CL2023000261A1 - Métodos de tratamiento de la neuralgia del trigémino - Google Patents
Métodos de tratamiento de la neuralgia del trigéminoInfo
- Publication number
- CL2023000261A1 CL2023000261A1 CL2023000261A CL2023000261A CL2023000261A1 CL 2023000261 A1 CL2023000261 A1 CL 2023000261A1 CL 2023000261 A CL2023000261 A CL 2023000261A CL 2023000261 A CL2023000261 A CL 2023000261A CL 2023000261 A1 CL2023000261 A1 CL 2023000261A1
- Authority
- CL
- Chile
- Prior art keywords
- trigeminal neuralgia
- treatment methods
- neuralgia treatment
- subject
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063058630P | 2020-07-30 | 2020-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023000261A1 true CL2023000261A1 (es) | 2023-09-08 |
Family
ID=77520687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023000261A CL2023000261A1 (es) | 2020-07-30 | 2023-01-26 | Métodos de tratamiento de la neuralgia del trigémino |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20230172922A1 (https=) |
| EP (1) | EP4188370A1 (https=) |
| JP (1) | JP2023540849A (https=) |
| KR (1) | KR20230047132A (https=) |
| CN (1) | CN115989024A (https=) |
| AR (1) | AR123108A1 (https=) |
| AU (1) | AU2021316675A1 (https=) |
| BR (1) | BR112023001621A2 (https=) |
| CA (1) | CA3182457A1 (https=) |
| CL (1) | CL2023000261A1 (https=) |
| IL (1) | IL300124A (https=) |
| MX (1) | MX2023001288A (https=) |
| PH (1) | PH12023550204A1 (https=) |
| TW (1) | TW202220649A (https=) |
| WO (1) | WO2022023519A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100548299C (zh) * | 2001-01-05 | 2009-10-14 | 伊莱利利公司 | 兴奋性氨基酸受体拮抗剂 |
| UA80888C2 (en) | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
| NZ551253A (en) * | 2004-06-01 | 2010-07-30 | Hoffmann La Roche | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists |
| MY148217A (en) * | 2006-12-21 | 2013-03-29 | Hoffmann La Roche | Polymorphs of a mglur5 receptor antagonist |
| US8211882B2 (en) * | 2008-03-08 | 2012-07-03 | Richard Delarey Wood | Glutamate receptor modulators and therapeutic agents |
| WO2011035209A1 (en) * | 2009-09-17 | 2011-03-24 | Vanderbilt Universtiy | Substituted benzamide analogs as mglur5 negative allosteric modulators and methods of making and using the same |
-
2021
- 2021-07-30 BR BR112023001621A patent/BR112023001621A2/pt unknown
- 2021-07-30 KR KR1020237006497A patent/KR20230047132A/ko active Pending
- 2021-07-30 MX MX2023001288A patent/MX2023001288A/es unknown
- 2021-07-30 CN CN202180049062.XA patent/CN115989024A/zh active Pending
- 2021-07-30 IL IL300124A patent/IL300124A/en unknown
- 2021-07-30 JP JP2023505820A patent/JP2023540849A/ja active Pending
- 2021-07-30 AR ARP210102142A patent/AR123108A1/es unknown
- 2021-07-30 TW TW110128158A patent/TW202220649A/zh unknown
- 2021-07-30 CA CA3182457A patent/CA3182457A1/en active Pending
- 2021-07-30 PH PH1/2023/550204A patent/PH12023550204A1/en unknown
- 2021-07-30 WO PCT/EP2021/071376 patent/WO2022023519A1/en not_active Ceased
- 2021-07-30 EP EP21762351.1A patent/EP4188370A1/en active Pending
- 2021-07-30 AU AU2021316675A patent/AU2021316675A1/en active Pending
-
2023
- 2023-01-26 CL CL2023000261A patent/CL2023000261A1/es unknown
- 2023-01-27 US US18/102,532 patent/US20230172922A1/en not_active Abandoned
-
2025
- 2025-07-18 US US19/273,884 patent/US20250345320A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202220649A (zh) | 2022-06-01 |
| EP4188370A1 (en) | 2023-06-07 |
| CN115989024A (zh) | 2023-04-18 |
| AU2021316675A1 (en) | 2023-01-19 |
| AR123108A1 (es) | 2022-10-26 |
| US20230172922A1 (en) | 2023-06-08 |
| WO2022023519A1 (en) | 2022-02-03 |
| MX2023001288A (es) | 2023-04-28 |
| CA3182457A1 (en) | 2022-02-03 |
| IL300124A (en) | 2023-03-01 |
| PH12023550204A1 (en) | 2024-06-24 |
| US20250345320A1 (en) | 2025-11-13 |
| BR112023001621A2 (pt) | 2023-04-04 |
| KR20230047132A (ko) | 2023-04-06 |
| JP2023540849A (ja) | 2023-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY37272A (es) | Piridinas sustituidas con heteroarilo y métodos de uso | |
| CL2020001945A1 (es) | Compuestos. | |
| DOP2020000050A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| CO2020004249A2 (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso | |
| CL2024000373A1 (es) | Compuesto inductor de la degradación de plk1 novedoso | |
| CO2020006523A2 (es) | Compuestos moduladores de sting y métodos de elaboración y uso | |
| CL2017002693A1 (es) | Métodos para tratar infecciones por el virus filoviridae. divisional de solicitud n° 1040-2017. | |
| UY36702A (es) | Piridinas sustituidas y métodos de uso | |
| UY37706A (es) | Compuestos antitumorales | |
| CL2023000594A1 (es) | Compuestos heterocíclicos | |
| CO2022014673A2 (es) | Nuevos compuestos útiles para el tratamiento y/o prevención de una enfermedad, trastorno o afección asociada con la angiotensina ii | |
| MX2022007670A (es) | Compuestos antihelminticos que comprenden una estructura de quinolina. | |
| MX2021016049A (es) | Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas. | |
| BR112022012130A2 (pt) | Compostos antelmínticos compreendendo uma estrutura azaindólica | |
| MY207276A (en) | Modulators of trex1 | |
| NI202000062A (es) | Régimen posológico del modulador del ensamblaje de la cápside | |
| MX2021015572A (es) | Compuesto de pirazolopirimidina, método de preparación para el mismo y sus aplicaciones. | |
| AR108344A1 (es) | 6-AMINOPIRIDIN-3-IL TIAZOLES COMO MODULADORES DE RORgT | |
| CL2020003248A1 (es) | Derivados de tetrahidrotienopiridina n-sustituidos y sus usos | |
| ECSP21003171A (es) | Dinucleótidos cíclicos como agonistas de sting | |
| CL2022003435A1 (es) | Métodos de tratamiento del complejo de esclerosis tuberosa | |
| MY193946A (en) | Functionalised polysulphide synthesis method | |
| EA201891808A1 (ru) | Трис-амидные соединения и композиции, содержащие их | |
| CL2023000261A1 (es) | Métodos de tratamiento de la neuralgia del trigémino | |
| MX2022008016A (es) | Compuesto antagonista de pd-l1. |